Pawel Fludzinski

Dr Fludzinski became CEO of AmideBio in May, 2018. Prior to AmideBio, he had a 31 year career with Eli Lilly and Company, with 23 years in executive leadership positions in the United States, United Kingdom, and Japan, encompassing roles in strategy, research and drug development. In addition, he was one of the founding members of Lilly BioVentures. In his final role at Lilly, he served as Global Brand Development Leader within the Diabetes Business Unit at Lilly where he led a cross functional team though Phase 2, Phase 3 clinical development and global registration of TRULICITY, Lilly’s once-a week agent for glycemic control in type 2 diabetes. He holds a Ph.D. in organic chemistry from the University of Rochester, Rochester NY, and was a National Institutes of Health Postdoctoral Fellow at Columbia University, New York City, NY.